fenfluramine for Dravet
Selected indexed studies
- Fenfluramine for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome. (CNS Drugs, 2020) [PMID:32875491]
- Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. (Lancet, 2019) [PMID:31862249]
- Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice. (Epilepsia Open, 2024) [PMID:38962968]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. (2024) pubmed
- Fenfluramine for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome. (2020) pubmed
- Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. (2019) pubmed
- Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice. (2024) pubmed
- Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. (2023) pubmed
- Fenfluramine for treatment-resistant epilepsy in Dravet syndrome and other genetically mediated epilepsies. (2021) pubmed
- Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine? (2022) pubmed
- Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial. (2020) pubmed
- PMID:40493732 (2022) pubmed
- A review of fenfluramine for the treatment of Dravet syndrome patients. (2022) pubmed